EVLA and Optimal Timing of Sclerotherapy

NANot yet recruitingINTERVENTIONAL
Enrollment

350

Participants

Timeline

Start Date

March 15, 2021

Primary Completion Date

March 15, 2027

Study Completion Date

March 15, 2030

Conditions
Venous Reflux
Interventions
PROCEDURE

Endovenous laser ablation

The aim is to combine the significance of for sclerotherapy at the primary EVLA treatment

Trial Locations (1)

20520

Turku University Hospital, Turku

All Listed Sponsors
collaborator

Helsinki University Central Hospital

OTHER

collaborator

Oulu University Hospital

OTHER

collaborator

Tampere University Hospital

OTHER

collaborator

Päijänne Tavastia Central Hospital

OTHER

collaborator

Satasairaala

OTHER

collaborator

Vaasa Central Hospital, Vaasa, Finland

OTHER

lead

Turku University Hospital

OTHER_GOV

NCT04774939 - EVLA and Optimal Timing of Sclerotherapy | Biotech Hunter | Biotech Hunter